The Link Between Gross Profitability And Pharmaceutical R&D Spending
Top Cited Papers
Open Access
- 1 September 2001
- journal article
- Published by Health Affairs (Project Hope) in Health Affairs
- Vol. 20 (5), 216-220
- https://doi.org/10.1377/hlthaff.20.5.216
Abstract
Pharmacy costs are rising in excess of general and medical cost inflation, leading to calls for price and utilization controls by public and private payers. Such controls would be ineffective and counterproductive because they would attempt to reverse two profound, historic phenomena at work in the U. S. health care system. The added costs associated with breakthrough medicines represent a major structural shift from the provision of traditional medical services to the consumption of medical products; they also represent the creation of economic, social, and public health utility that we value as a society. The balkanization of medical delivery, institutionalized under traditional reimbursement strategies and galvanized by federal law, does not adequately account for or efficiently accommodate this rotation and increased utility. Federal and state laws regulating health insurance and provider risk sharing need to be revamped to encourage rather than constrain the social progress embodied in expensive, breakthrough medical technologies.Keywords
This publication has 6 references indexed in Scilit:
- R & D and Internal Finance: A Panel Study of Small Firms in High-Tech IndustriesThe Review of Economics and Statistics, 1994
- Estimating the impact of the R&D tax credit on strategic groups in the pharmaceutical industryResearch Policy, 1993
- A New Look at the Returns and Risks to Pharmaceutical R&DManagement Science, 1990
- Demand-Pull and Technological Invention: Schmookler RevistedJournal of Industrial Economics, 1982
- Optimal Timing of InnovationsThe Review of Economics and Statistics, 1968
- The Determinants of Industrial Research and Development: A Study of the Chemical, Drug, and Petroleum IndustriesJournal of Political Economy, 1968